Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers
Condition: HPV 16+ Recurrent or Metastatic Cancer Interventions: Biological: CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16; Biological: Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16 Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; PapiVax Biotech, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Biotechnology | Bone Marrow Transplant | Cancer | Cancer & Oncology | Cancer Vaccines | Research | Transplants | Vaccines